Drug intelligence / Profile preview

LY3295668 + osimertinib

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of LY3295668 (also known as AK-01 or Erbumine) and osimertinib. LY3295668 is an orally bioavailable, selective Aurora Kinase A inhibitor that targets and inhibits the activity of aurora A kinase, potentially disrupting mitotic spindle assembly and inducing apoptosis in cancer cells. Osimertinib is an EGFR tyrosine kinase inhibitor that targets specific EGFR mutations. This combination is being investigated for the treatment of advanced or metastatic EGFR-mutant non-small cell lung cancer.

Other names: LY3295668 erbumine + osimertinibAK-01 + osimertinibErbumine + osimertinib

Targets

AURKA (Aurora kinase A)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on LY3295668 + osimertinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3295668 + osimertinib.

Explore the full profile